USA - NASDAQ:ABMD - US0036541003 - Common Stock
ChartMill assigns a Buy % Consensus number of 70% to ABMD. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-11-02 | Deutsche Bank | Downgrade | Buy -> Hold |
| 2022-11-02 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2022-11-01 | William Blair | Downgrade | Outperform -> Market Perform |
| 2022-11-01 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2022-10-13 | Mizuho | Initiate | Buy |
| 2022-10-10 | Piper Sandler | Maintains | Overweight |
| 2022-07-21 | Deutsche Bank | Maintains | Buy |
| 2022-07-15 | Morgan Stanley | Maintains | Underweight |
| 2022-02-04 | SVB Leerink | Maintains | Market Perform |
| 2022-02-04 | Morgan Stanley | Maintains | Underweight |
| 2022-01-07 | Morgan Stanley | Maintains | Underweight |
| 2021-08-06 | SVB Leerink | Maintains | Market Perform |
| 2021-07-20 | SVB Leerink | Maintains | Market Perform |
| 2021-06-18 | Deutsche Bank | Initiate | Buy |
16 analysts have analysed ABMD and the average price target is 375.36 USD. This implies a price decrease of -1.49% is expected in the next year compared to the current price of 381.02.
The consensus rating for ABIOMED INC (ABMD) is 70 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
The number of analysts covering ABIOMED INC (ABMD) is 16.